Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438 16/09/2025

4,195 CHF (+9,10%)

(+9,10%) 16/09/2025

Grafiek Idorsia Ltd

Grafiek Idorsia Ltd

1 dag1d 9,10%
1 week1w 24,11%
1 maand1m 53,66%
3 maanden3m 93,76%
6 maanden6m 255,51%
1 jaar1j 163,01%
5 jaar5j -83,65%

Idorsia Ltd in het nieuws

Toon enkel gratis nieuws

10 september 2025 · Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025 · Persbericht

8 september 2025 · Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025 · Persbericht

5 september 2025 · Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension · Persbericht

3 september 2025 · Invitation to Idorsia’s aprocitentan (TRYVIO/JERAYGO) investor Q&A webcast and conference call · Persbericht

1 september 2025 · Idorsia furthers the science of sleep and insomnia at World Sleep 2025 · Persbericht

28 augustus 2025 · Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension · Persbericht

27 augustus 2025 · Idorsia successfully completes convertible bonds restructuring · Persbericht

19 augustus 2025 · TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension · Persbericht

19 augustus 2025 · Idorsia publishes end results of repurchase offer for its 2025 and 2028 convertible bonds · Persbericht

12 augustus 2025 · TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product” · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe